Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan.
Daiichi Sankyo Co. Ltd. was established in 2005 with the merger of two leading century-old pharmaceutical companies, Daiichi Pharmaceutical Co.,Ltd. and Sankyo Co., Ltd.Headquartered in Tokyo, the company is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.

Report: Partnering Deals and Alliances with Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan.

Daiichi Sankyo Co. Ltd. was established in 2005 with the merger of two leading century-old pharmaceutical companies, Daiichi Pharmaceutical Co.,Ltd. and Sankyo Co., Ltd.

Headquartered in Tokyo, the company is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.

Daiichi Sankyo maintains a portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections around the world and also focuses on the discovery of novel oncology therapies.

The company strives to accomplish its vision by acquiring new product candidates, new products and/or companies that will drive its portfolio in key therapeutic categories. It  is actively engaged in continously improving its R&D processes for medicines in:

  • Oncology
  • Cardiovascular and Metabolic Disorders
  • “Frontier” – innovative discoveries in a variety of mechanisms and diseases

Daiichi Sankyo has an active licensing venture investment and acquisition group charged with analysing and managing all incoming opportunities more

Daiichi Sankyo announced over 47 partnering / licensing deals since its inception in 2005, with atleast 10 deals in 2011 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in cardiovascular, cancer, followed by infectives and metabolic diseases more

Daiichi Sankyo has also announced over 5 M&A deals since 2005, with the lead deals being the acquisition of Plexxikon, Zenotech and Ranbaxy Laboratories more

Report: Partnering Deals and Alliances with Daiichi Sankyo

Examples of recent partnering and licensing deals announced by Daiichi Sankyo can be viewed in Current Partnering's Partnering Agreements with Daiichi Sankyo 2005-2013 review article.

Our report provides more detailed insight into the details of each deal.

See: Partnering Deals and Alliances with Daiichi Sankyo

Available reports from Current Partnering

Report: Partnering Deals and Alliances with Daiichi Sankyo

Report: Partnering Deals and Alliances with Big Pharma

 

Available resources for deal coverage for Daiichi Sankyo

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Daiichi Sankyo company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Print Friendly, PDF & Email